3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
8
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Urinary Bladder Neoplasms
5
Leukemia, Myeloid, Acute
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Mouth Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Ureteral Neoplasms
2
Stomatitis
2
Recurrence
2
Oropharyngeal Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
COVID-19
2
Brain Neoplasms
2
Adenocarcinoma
2
Interventions
Gemcitabine
58
Cisplatin
32
Oxaliplatin
28
Fluorouracil
21
lenvatinib
19
durvalumab
18
Capecitabine
17
Leucovorin
15
tislelizumab
10
pembrolizumab
10
apatinib
9
Floxuridine
8
Specimen Handling
7
Panitumumab
7
Magnetic Resonance Spectroscopy
7
Albumin-Bound Paclitaxel
7
sintilimab
6
pemigatinib
6
Radiotherapy
6
Irinotecan
6
Drug Therapy
6
Biopsy
6
tremelimumab
5
regorafenib
5
olaparib
5
camrelizumab
5
Taxes
5
S 1 (combination)
5
Nivolumab
5
Folfox protocol
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cholangiocarcinoma
×
Standard of Care
×
Clear all
NCT04099888
2023-09-11
RELEASE
PCI Biotech AS
Phase 2
Terminated
41 enrolled
17 charts